Weed (BUDZ) Cost of Revenue (2022)

Weed (BUDZ) posted quarterly Cost of Revenue of -$2230.0 for Q4 2022, down 200.0% quarter-over-quarter from $2230.0 in Q3 2022.

Weed (BUDZ) Cost of Revenue (2022) Analysis & Trends

Weed's Cost of Revenue history runs 1 years deep, the most recent figure standing at -$2230.0 for Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Haleon	43.81 Bn	42.84 Bn	-	-
2	Teva Pharmaceutical Industries	43.29 Bn	39.63 Bn	2.15 Bn	1.99 Bn
3	Zoetis	31.59 Bn	29.91 Bn	1.05 Bn	673.00 Mn
4	Takeda Pharmaceutical	28.67 Bn	22.88 Bn	5.10 Bn	2.55 Bn
5	United Therapeutics	22.24 Bn	19.58 Bn	683.80 Mn	99.50 Mn
6	Viatris	18.79 Bn	17.91 Bn	1.46 Bn	2.30 Bn
7	Neurocrine Biosciences	15.71 Bn	15.32 Bn	935.80 Mn	23.20 Mn
8	Elanco Animal Health	12.09 Bn	11.56 Bn	798.00 Mn	570.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-	-
10	Weed	2.88 Mn	2.88 Mn	-	-

Download Data